Advances in the development of new biomarkers for Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 238 of the 238 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most common type of neurodegenerative dementia. The prevalence of AD is expected to increase as the population ages, placing an additional burden on national healthcare systems. There is a large need for new diagnostic tests that can detect AD at an early stage with high specificity at relatively low cost. The development of modern analytical diagnostic tools has made it possible to determine several biomarkers of AD with high specificity, including pathogenic proteins, markers of synaptic dysfunction, and markers of inflammation in the blood. There is a considerable potential in using microRNA (miRNA) as markers of AD, and diagnostic studies based on miRNA panels suggest that AD could potentially be determined with high accuracy for individual patients. Studies of the retina with improved methods of visualization of the fundus are also showing promising results for the potential diagnosis of the disease. This review focuses on the recent developments of blood, plasma, and ocular biomarkers for the diagnosis of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many CSF biomarkers (like Aβ, P-tau, NfL, GFAP) also show promising applications in blood, with advancements in highly sensitive analytical platforms and detection techniques enhancing diagnostic precision and reliability.368,388,389”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [368]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Studies have reported that amyloid PET exhibits 90% sensitivity and specificity in diagnosing AD, and tau PET can specifically identify AD dementia from other neurodegenerative diseases, showing higher diagnostic accuracy than MRI markers.368”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [368]
The cited source says what the claim attributes to it.
In the citing paper
“Studies have reported that amyloid PET exhibits 90% sensitivity and specificity in diagnosing AD, and tau PET can specifically identify AD dementia from other neurodegenerative diseases, showing higher diagnostic accuracy than MRI markers.368”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [368]
The cited source says what the claim attributes to it.
In the citing paper
“Peripheral biomarkers are increasingly recognized as valuable for detecting early brain changes in MCI and AD, supporting diagnostic and therapeutic strategies at preclinical stages. 13”
From Plasma extracellular vesicles from APOE3 Christchurch carriers display a protective phenotype in early stages of autosomal dominant Alzheimer's disease (2026) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Huang, D., Swanson, E. A., Lin, C. P., Schuman, J. S., Stinson, W. G., Chang, W., Hee, M. R., Flotte, T., Gregory, K., Puliafito, C. A., et al. (1991) · Science · doi:10.1126/science.1957169 · Cited by 13,788
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Regulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462 · cited 1×
“MicroRNA (miRNA) biomarkers of AD Mature miRNAs are single-stranded RNA molecules of 20–25 nucleotides [134] that can regulate gene expression post-transcriptionally by binding to the 3’-untranslated region (3’UTR) of mRNAs and blocking protein synthesis or leading to the degradation of target mRNAs [135].”
BackgroundAnderson, N. L., & Anderson, N. G. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r200007-mcp200 · Cited by 4,414
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411 · cited 1×
“The development of AD goes through three stages: the pre-symptomatic stage, the prodromal stage of mild cognitive impairment (MCI), and the clinical form of AD [4, 5].”
BackgroundClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“Currently, AD can be identified in patients at the preclinical stage in vivo, for example, by the biological or molecular signature of the disease [13].”
BackgroundAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204 · cited 2×
“Indeed, Aβ which is normally cleared by microglia can induce an activation phenotype of microglia, leading to chemokine release and local inflammation [15, 20].”
BackgroundNeuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179 · cited 1×
“While Aβ and Tau pathologies have a well-documented impact on brain physiology in AD, their appearance and accumulation are a consequence of early impairment of immune functions and arising neuroinflammation [18].”
Background2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 1×
“Furthermore, Tau pathologies alone can trigger neurodegeneration and the progression of Tau pathologies correlates with the severity of the cognitive impairment [17].”
Background
Research works printed but not linked: 1
- Zeng Q, Zou L, Qian L, Zhou F, Nie H, Yu S, et al. Expression of microRNA-222 in serum of patients with Alzheimer’s disease. Mol Med Rep. 2017;16(4):5575–9. · DOI
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“366 368 However, sMRI and ( 18 FDG)-PET indicate neuro-degeneration or neuronal injury in the AT(N) framework with limitations in speci fi cally diagnosing AD.”
BackgroundPathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Kamatham, P. T., Shukla, R., Khatri, D. K., & Vora, L. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102481 · Cited by 371
“Elevated levels of total tau in CSF were the first possible biomarker reported in 1993 (Klyucherev et al., 2022).”
BackgroundGlial Cell-Mediated Neuroinflammation in Alzheimer’s Disease
Al-Ghraiybah, N. F., Wang, J., Alkhalifa, A. E., Roberts, A. B., Raj, R., Yang, E., & Kaddoumi, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810572 · Cited by 202
The role of microRNAs in neurodegenerative diseases: a review
Li, S., Lei, Z., & Sun, T. (2023) · Cell Biology and Toxicology · doi:10.1007/s10565-022-09761-x · Cited by 183
“Reproduced with permission from reference (Klyucherev et al. 2022).”
Vrahatis, A. G., Skolariki, K., Krokidis, M. G., Lazaros, K., Exarchos, T. P., & Vlamos, P. (2023) · Sensors · doi:10.3390/s23094184 · Cited by 166
“Furthermore, analysis of blood-based samples can also provide early indications of AD pathology, by measuring levels of AD-related proteins such as A β and tau [14].”
Background
Metadata
- Authors
- Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B.
- Affiliations
- Uppsala University (SE)
- Sechenov University (RU)
- Corresponding author
- Schiöth, Helgi B.
- ORCID
- Venue
- Translational Neurodegeneration
- Published
- 2022-04-21
- Volume
- 11
- Issue
- 1
- Pages
- 25-25
- ISSN
- 2047-9158 (ISSN-L)
- PMC
- PMC9027827
- OpenAlex
- W4224247151
- Cited by
- 241
- References
- 238
- Citations by year
- 2026: 34 · 2025: 65 · 2024: 85 · 2023: 47 · 2022: 10
- FWCI
- 8.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Translational Neurodegeneration (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- vetenskapsrådet
- hjärnfonden
- Uppsala University
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, biomarkers, early diagnosis, blood biomarkers, plasma biomarkers, ocular biomarkers, retina, microRNA, synaptic dysfunction, neuroinflammation, pathogenic proteins, diagnostic testing
- MeSH terms
- Alzheimer Disease, Humans, Retina, Biomarkers, Amyloid beta-Peptides, MicroRNAs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in the development of new biomarkers for Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s40035-022-00296-z
- The paper
- Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B. (2022). Advances in the development of new biomarkers for Alzheimer’s disease. Translational Neurodegeneration. https://doi.org/10.1186/s40035-022-00296-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.